Immune-Related Adverse Events for Lung Toxicity - Pneumonitis

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
grade
—grade
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Grade 11–1
  • Grade 22–2
  • Grade 33–3
  • Grade 44–4
Direct Clinical Answer

The Immune-Related Adverse Events for Lung Toxicity - Pneumonitis calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include respiratory symptoms. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Grades severity of pneumonitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates respiratory symptoms, oxygen requirements, and functional impact to determine the severity of immune-mediated pneumonitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, pulmonology consultation needs, and monitoring for life-threatening respiratory complications. ICPi-induced pneumonitis has an incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis in single-agent therapy. The calculator provides evidence-based management recommendations essential for oncologists, pulmonologists, and intensive care teams managing patients on immunotherapy.

Clinical Indication

The Immune-Related Adverse Events for Lung Toxicity - Pneumonitis is indicated for bedside clinical practice to support Grades severity of pneumonitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates respiratory symptoms, oxygen requirements, and functional impact to determine the severity of immune-mediated pneumonitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, pulmonology consultation needs, and monitoring for life-threatening respiratory complications. ICPi-induced pneumonitis has an incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis in single-agent therapy. The calculator provides evidence-based management recommendations essential for oncologists, pulmonologists, and intensive care teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Onset typically occurs 2-24 weeks after treatment initiation (median 2.8 months).

Formula & Variables:

CTCAE grading based on symptom severity, functional impact, oxygen requirements, and radiographic extent: Grade 1: Asymptomatic with radiographic changes; Grade 2: Symptomatic limiting instrumental ADLs; Grade 3: Severe symptoms limiting self-care ADLs, oxygen indicated; Grade 4: Life-threatening respiratory compromise requiring urgent intervention

Input Parameters

NameTypeRequiredDescription
respiratory_symptomsstringYesPresence and severity of respiratory symptoms including dyspnea, cough, chest pain. Asymptomatic indicates radiographic changes only without symptoms. Mild symptoms allow normal daily activities. Moderate symptoms limit some activities. Severe symptoms significantly limit activities
functional_impactstringYesImpact on activities of daily living and functional status. None: normal activities maintained. Limiting instrumental ADLs: some limitation in complex activities. Limiting self-care ADLs: unable to perform basic self-care activities. Life-threatening: requires urgent intervention
oxygen_requirementstringYesNeed for supplemental oxygen or respiratory support. Room air: no oxygen needed. Low-flow oxygen: nasal cannula ≤4L/min. High-flow oxygen: >4L/min or non-rebreather mask. Mechanical ventilation: intubation or non-invasive positive pressure ventilation required
radiographic_findingsstringYesExtent of radiographic involvement on chest imaging (CT preferred). Normal: no findings. Minimal: <25% lung involvement. Moderate: 25-50% lung involvement. Extensive: >50% lung involvement or diffuse bilateral involvement
hospitalization_indicatedstringYesClinical indication for hospitalization based on severity, oxygen requirements, or complications. Indicates at least Grade 2 severity. Consider for respiratory distress, hypoxemia, or need for close monitoring

Score Interpretation & Guidance

RangeStageDescription
1–1Grade 1Mild - Asymptomatic; clinical or diagnostic observations only
2–2Grade 2Moderate - Symptomatic; limiting instrumental ADLs
3–3Grade 3Severe - Limiting self-care ADLs; oxygen indicated
4–4Grade 4Life-threatening - Life-threatening respiratory compromise; urgent intervention indicated

Evidence-Based References (EBM)

  • Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.DOI: 10.1200/JCO.2017.77.6385
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.DOI: 10.6004/jnccn.2020.0012
  • Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453.DOI: 10.1001/jamaoncol.2016.2453
  • Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017 Mar 10;35(7):709-717. doi: 10.1200/JCO.2016.68.2005.DOI: 10.1200/JCO.2016.68.2005

Related calculators